Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Dexcom designs and commercializes continuous ... and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Both groups used a Dexcom G6 Continuous Glucose Monitoring (CGM ... The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ ...

DexCom projects 2025 revenue of $4.6 billion ... additional 20 million U.S. type 2 diabetes patients not currently on insulin. Q4 adjusted EPS of $0.45 compared to analysts' estimate of $0. ...

and integration with insulin pumps and digital health platforms. DexCom, Inc. (NASDAQ:DXCM) delivered strong performance in 2024 with revenue of $4.33 billion and organic growth of 12% ...

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Investors with significant funds have taken a bearish position in DexCom (NASDAQ:DXCM), a development that retail traders should be aware of. This was brought to our attention today through our ...